Sarasin has introduced the Sarasin global health fund, an Oeic that aims to produce capital growth by investing in global healthcare and medical developments.
The fund will look at three sectors: pharmaceuticals, biotechnology and medical technology. It will select stocks within these areas according to themes, such as the technological innovation and the prevention and cure of disease. Businesses that are most likely to benefit from these themes will be considered for the portfollio. These may be small, medium or large companies.
Healthcare is seen by Sarasin as a good investment opportunity because people are now more health conscious because there is increasing demand for vaccines, medicines and medical equipment.
The fund management team will be led by Dr Irene Püttner, who has 14 years experience in research and business development in the biotechnology and pharmaceutical industries in Europe and the US.
Healthcare is a good area to invest in because it is less dependent on economic factors than some sectors and people will always need healthcare. According to Owain Kember, marketing manager of funds supermarket Funds Direct, the Sarasin fund's diversification across industrial sectors distinguishes it from other healthcare funds such as Framlington health and Schroder Medical discovery. However, the global diversification of the Sarasin fund may be compromised by the fact that many of the companies in the healthcare field are based in the US.
According to Standard & Poor's, the Sarasin EquiSar global thematic fund is ranked 100 out of 127 funds based on £1,000 invested on a bid-to-bid basis with net income reinvested over three years to March 1, 2002.